Portage end of Q2 2017 Update – $PTGEF

As Q2 2017 comes to an end, it’s a great time to reflect on past calls and reevaluate if necessary.

My two and only picks so far, Medivation and Portage Biotech have yielded spectacular results.

The call on Medivation was dead on and returned massive gains.

The call on Portage Biotech has been equally impressive, returning 550% to date.

As Portage approaches within 10% of my lower end target of .45, I suggest taking a few chips off the table. Nothing wrong with taking some profit at .41+- and creating some dry powder in the event the shares back off.

I don’t expect much news in Q3 but I’m looking forward to a very busy Q4 for Portage.

Thank you to our subscribers who have taken the time to write in and thank us!

Happy July 4th!





Contrarian's Mind

Born in Toronto Lived in Nassau,Bahamas - Palm Beach,Florida - Las Vegas,Nevada and now residing in beautiful Barcelona,Spain. I back bright entrepreneurs with big ideas related to Artificial Intelligence, Machine Learning, realtime platforms and price discovery. Make everyday remarkable!

  1. I like ptgef and still think there is more unlocked potential in the cos that are yet developed yet either thru ppl,sentinen,Biohavens and Cleo

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.